US Patent Issued to Beijing Carrius Bio on Sept. 1 for "Spleen-targeted ionizable lipid compound, composition comprising same and use thereof" (Chinese Inventor)

ALEXANDRIA, Va., Sept. 1 -- United States Patent no. 12,723,016, issued on Sept. 1, was assigned to Beijing Carrius Bio Ltd. (Beijing).

"Spleen-targeted ionizable lipid compound, composition comprising same and use thereof" was invented by Ming Wang (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides an ionizable lipid compound, which can target spleen for delivery of biological macromolecules including nucleic acid drugs or nucleic acid vaccines with high efficiency. The present invention also relates to a lipid nanoparticle (LNP) comprising the ionizable lipid compound and an active molecule, and a pharmaceutical composition comprising the lipid nanoparticle."

The patent...